-
Dr. Jiong Wu: Enhancing Knowledge Exchange, Expanding Achievements in Breast Conservation and Reconstruction; Grasping New Trends in Neoadjuvant Immunotherapy| 16th Shanghai Breast Reconstruction Conference
From October 15-17, 2024, the 16th Shanghai Breast Reconstruction Conference and 5th Shanghai Breast Reconstruction Nursing Forum were successfully held, organized by the Chinese Anti-Cancer Association’s Breast Cancer Integration Committee and the Shanghai Anti-Cancer Association and hosted by Fudan University Shanghai Cancer Center. The conference focused on the status of breast conservation and reconstruction in…
-
SIBCS 2024 | Dr. Li Ma: Advances in Breast Surgery and Pathology Techniques and Prospects for the 2025 “Little Red Book” Updates
At the 2024 SIBCS conference, Dr. Li Ma from The Fourth Hospital of Hebei Medical University presented on the topic “Advances and Controversies in Breast Surgery and Pathology.” He addressed various hot topics, including: “Can axillary dissection be completely avoided in patients with 1–2 positive sentinel lymph nodes? Can axillary dissection be omitted after downstaging…
-
SIBCS 2024 | Dr. Qiang Liu: Major Clinical Trial Achievements in China’s Breast Cancer Treatment and Emerging Trends in Precision Therapy
n recent years, breast cancer treatment in China has undergone a remarkable transformation, from drug accessibility to treatment paradigms, aligning more closely with global standards. At the 2024 SIBCS conference, Dr. Qiang Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, delivered an insightful presentation on “Major Clinical Trial Achievements in China’s Breast Cancer Treatment,”…
-
Klebsiella pneumoniae: Leading Bacterial Killer in Clinical Settings – Dr. Chen Sheng Shares Advances at One Health Conference
1. Infectious Diseases Frontier: What global challenges does Klebsiella pneumoniae, as a significant drug-resistant pathogen, pose to public health? What are the primary difficulties in controlling its infections? Dr. Sheng…
-
WCLC 2024 | Dr. Kenneth O’Byrne：Spatial Metabolic Mapping Accelerates Biomarker Development for Predicting ICI Therapy Responses
Immune checkpoint inhibitors (ICIs) have brought new hope to the treatment of non-small cell lung cancer (NSCLC). However, their effectiveness is limited to only a subset of patients. Current biomarkers, such as tumor mutational burden (TMB) and PD-L1, show limited predictive power. According to Dr. Kenneth O’Byrne’s report(Icon Cancer Centre Greenslope) at the 2024 World…
-
Congratulations！iLIVER Executive Editor Tian Yang Awarded “National Distinguished Youth Scholar”
The review results of the 2024 National Natural Science Foundation of China (NSFC) centralized application period projects were recently announced. Dr. Tian Yang from the Third Affiliated Hospital of Naval Medical University was awarded the National Distinguished Youth Science Fund Project.
-
Dr. Meiqi Shi’s In-Depth Discussion: Key Topics in Lung Cancer Immunotherapy | CSCO Lung Cancer Standardized Treatment Workshop
Since the FDA approval of the first lung cancer immunotherapy regimen in 2015 based on the CheckMate-017 and 057 studies, lung cancer immunotherapy has evolved significantly over the past decade, becoming the first-line standard of care for patients with driver mutation-negative non-small cell lung cancer (NSCLC). However, as evidence accumulates and clinical experience grows, some…
-
ESMO 2024 | Dr. Tian Yang on New Liver Cancer Screening Method using Digital PCR Detection of Circulating Tumor DNA Methylation Markers
Liver cancer, often referred to as the “silent killer,” is frequently diagnosed at an advanced stage. Current screening methods such as alpha-fetoprotein (AFP) testing and ultrasound lack sufficient sensitivity and specificity. Therefore, there is an urgent need for more efficient, accurate, and cost-effective screening tools. At the 2024 ESMO conference, former President of the Korean…
Connecting Medical Expertise through Media